Brief: Arcus Biosciences Announces That Domvanalimab Plus Zimberelimab Improved Overall Survival In Arc-10
05/11/2024 14:12
Nov 5 (Reuters) - Arcus Biosciences Inc RCUS.N :
* ARCUS BIOSCIENCES ANNOUNCES THAT DOMVANALIMAB PLUS
ZIMBERELIMAB
IMPROVED OVERALL SURVIVAL IN ARC-10, A RANDOMIZED STUDY IN
PATIENTS WITH PD-L1-HIGH NON-SMALL CELL LUNG CANCER
* ARCUS BIOSCIENCES INC - LOWER TREATMENT-RELATED ADVERSE
EVENTS
FOR COMBINATION THERAPY
* ARCUS BIOSCIENCES INC - 36% REDUCTION IN RISK OF DEATH
OBSERVED
FOR COMBINATION THERAPY
Source text: ID:nBw4PRK07a
Further company coverage: RCUS.N
(Reuters.Briefs@thomsonreuters.com)
Recent news on Arcus Biosciences
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Arcus Biosciences tumbles on $250 mln share sale
Brief: Arcus Biosciences Announces Pricing Of $250 Million Public Offering Of Common Stock
Arcus Biosciences drops after starting stock offering